
    
      The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The
      patients will receive escitalopram for 12 weeks. Start and maintenance dosages as well as
      dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance
      with the national Summary of Products Characteristics (SPC).
    
  